Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

Autor: Michael Reiss, Daniel Zelterman, Rebecca Sipples, Vinni Juneja, Frans J. Th. Wackers, Bruce G. Haffty, Forrester A. Lee, Maysa M. Abu-Khalaf, Michael P. DiGiovanna, Meghan McGurk, Gina G. Chung, Barbara Burtness
Rok vydání: 2006
Předmět:
Zdroj: Breast cancer research and treatment. 104(3)
ISSN: 0167-6806
Popis: This study evaluated the incidence of late cardiotoxicity after dose-dense and -intense adjuvant sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) for breast cancer (BC) with ≥ 4 involved ipsilateral axillary lymph nodes. Patients were enrolled from 1994 to 2001 after definitive BC surgery if ≥4 axillary nodes were involved. Planned treatment was A 90 mg/m2 q 14 days × 3, T 250 mg/m2 q 14 days × 3, C 3 g/m2 q 14 days × 3 with filgrastim (G) support. Left ventricular ejection fraction (LVEF) was monitored using equilibrium radionuclide angiography (ERNA) before the initiation of chemotherapy, and after three cycles of each chemotherapeutic agent. At a median follow-up of 7 years, we obtained ERNA scans on 32 patients to evaluate the long-term cardiotoxicity of this regimen. Eighty-five eligible patients enrolled on the treatment protocol. Clinical heart failure developed in one patient. Seven (8%) patients had LVEF
Databáze: OpenAIRE